Marco Antonio Alcocer-Gamba

Dr. Marco Antonio Alcocer-Gamba

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Archives of Medical Research
Verified
Journal Article
Closed access
HRHumberto Rodríguez-Reyes
Humberto Rodríguez-Reyes
SLSusano Lara-Vaca
Susano Lara-Vaca
AOAna Ochoa-Guzmán
Ana Ochoa-Guzmán
ECErwin Chiquete
Erwin Chiquete
AAArturo Abundes-Velasco
Arturo Abundes-Velasco
JZJosé G. Zúñiga-Sedano
José G. Zúñiga-Sedano

15 August 2024 in Medicina
Verified
Journal Article
Open access
PDF file
LGLeslie Marisol Lugo Gavida
Leslie Marisol Lugo Gavida
MAMarco Antonio Alcocer-Gamba
Marco Antonio Alcocer-Gamba
AMAraceli Martinez-Cervantes
Araceli Martinez-Cervantes
The development of percutaneous coronary intervention (PCI) has been one of the greatest advances in cardiology and has changed clinical practice for patients with coronary artery disease (CAD). Despite continuous improvements in operators’ experience, techniques, and the development of new-generation devices, significant challenges remain in improving the efficacy of PCI, including calcification, bifurcation, multivascular disease, stent restenosis, and stent thrombosis, among others. The present review aims to provide an overview of the current status of knowledge of endovascular revascularization in CAD, including relevant trials, therapeutic strategies, and new technologies addressing particular scenarios that can impact the prognosis of this vulnerable population.

1 January 2020
Verified
Journal Article
Closed access
PDF file
CDCarlos Del-Río
Carlos Del-Río
MAMarco Antonio Alcocer-Gamba
Marco Antonio Alcocer-Gamba
MEMara Escudero-Salamanca
Mara Escudero-Salamanca
AGArturo Galindo-Fraga
Arturo Galindo-Fraga
JGJeannette Guarner
Jeannette Guarner
XEXavier Escudero
Xavier Escudero

3 February 2020 in Global Heart
Verified
Journal Article
Open access
PDF file
MMManlio F. Márquez
Manlio F. Márquez
MBManuel Alfonso Baños-González
Manuel Alfonso Baños-González
MGMilton E. Guevara-Valdivia
Milton E. Guevara-Valdivia
JVJorge Vázquez-Acosta
Jorge Vázquez-Acosta
MIManuel O. De Los Ríos Ibarra
Manuel O. De Los Ríos Ibarra
JGJesus Antonio Gonzalez- Hermosillo Gonzalez
Jesus Antonio Gonzalez- Hermosillo Gonzalez
Documenting the patterns of oral anticoagulation therapy (OAT) is essential to prevent thromboembolic complications of nonvalvular atrial fibrillation (NVAF). To report the patterns of OAT according to age and thromboembolic risk in patients included in CARMEN-AF, a nationwide registry of NVAF in Mexico, an upper middle-income country. There were 1,423 consecutive patients ≥18 years old and with at least one thromboembolic risk factor enrolled in the CARMEN-AF Registry at their regular clinical visit during a three-year period. They were analyzed according to 1) age, 2) AF type, and 3) CHA2DS2-VASc score. Overall, 16.4% of patients did not receive antithrombotic treatment, 19.4% received antiplatelet drugs (APD), 29.2% vitamin K antagonists (VKA), and 34.6% direct oral anticoagulants (DOAC). With increasing age, the proportion of subjects treated with VKA decreased significantly from 36.2% in subjects <65 years to 22.5% in those ≥75 years old (P <0.0001). Concomitantly, an increase in both APD and no antithrombotic treatment was observed with increasing age. DOAC were prescribed equally among all age groups (34.2% in <65, 36.0% in 65–74, and 33.9% in ≥75). According to the type of AF, VKA use was more common in patients with permanent AF (32.7%). A lower use of DOAC was observed in high thromboembolic risk subjects (33.6% in CHA2DS2-VASc ≥2) compared with the moderate risk group (41% in CHA2DS2-VASc = 1). VKA use for NVAF in Mexico decreased in relation to increasing age. The proportion of DOAC therapy was the same in all age groups. Nevertheless, elderly patients with high thromboembolic risk received a suboptimal thromboprophylaxis. These data could help to improve gaps in the implementation of global guidelines. http://www.clinicaltrials.gov. Unique identifier: NCT02334852.

1 October 2012 in Archivos de Cardiología de México
Verified
Journal Article
Open access
MAMarco Antonio Alcocer-Gamba
Marco Antonio Alcocer-Gamba
JMJorge A. Martínez-Chávez
Jorge A. Martínez-Chávez
MAMónica Alcántara-Razo
Mónica Alcántara-Razo
GEGuering Eid-Lidt
Guering Eid-Lidt
LLLeslie M. Lugo-Gavidia
Leslie M. Lugo-Gavidia
AVArturo Velázquez-Verduzco
Arturo Velázquez-Verduzco
Nutcracker's syndrome is caused by compression of the left renal vein between aorta and superior mesenteric artery, causing extrinsic compression generated functional stenosis. This causes congestion and hypertension of the left renal vein resulting in insufficiency and left gonadal vein varicose, unilateral hematuria and left flank pain, diagnosis is rarely identified by their low frequency and difficulty of suspecting, treatment of nutcracker's syndrome include renal autotransplantation, transposition of superior mesenteric artery revascularization and recently stenting in renal vein, we present the case of a patient, who showed this pathology by diagnostic support by image studies, was performed successfully implant a self-expanding stent with immediate success criteria by angiography, collateral reduction and by disappearance of cava/renal gradient.

30 September 2021 in Archivos de Cardiología de México
Verified
Journal Article
Open access
MAMarco Antonio Alcocer-Gamba
Marco Antonio Alcocer-Gamba
PGPedro Gutiérrez-Fajardo
Pedro Gutiérrez-Fajardo
ACAlfredo Cabrera-Rayo
Alfredo Cabrera-Rayo
ASAlejandro Sosa-Caballero
Alejandro Sosa-Caballero
YPYigal Piña-Reyna
Yigal Piña-Reyna
RRRomina Rivera-Reyes
Romina Rivera-Reyes